Helus Pharma is a clinical-stage pharmaceutical enterprise—originally founded as Cybin Inc.—that focuses on developing proprietary novel serotonergic agonists, which are synthetic molecules designed to target serotonin pathways and promote neuroplasticity for the treatment of psychiatric disorders. The company's therapeutic pipeline addresses significant unmet medical needs in areas such as major depressive disorder and generalized anxiety disorder. By engineering specialized chemical formulations designed to optimize treatment efficacy and manage duration profiles, the firm aims to transform the mental health treatment landscape through rigorous clinical trials conducted across international research sites.